CO2018007008A2 - "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" - Google Patents
"procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"Info
- Publication number
- CO2018007008A2 CO2018007008A2 CONC2018/0007008A CO2018007008A CO2018007008A2 CO 2018007008 A2 CO2018007008 A2 CO 2018007008A2 CO 2018007008 A CO2018007008 A CO 2018007008A CO 2018007008 A2 CO2018007008 A2 CO 2018007008A2
- Authority
- CO
- Colombia
- Prior art keywords
- azd9291
- salt
- osimertinib
- preparation
- improved processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662289390P | 2016-02-01 | 2016-02-01 | |
| PCT/EP2017/052050 WO2017134051A1 (en) | 2016-02-01 | 2017-01-31 | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018007008A2 true CO2018007008A2 (es) | 2018-07-19 |
Family
ID=57984913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0007008A CO2018007008A2 (es) | 2016-02-01 | 2018-07-04 | "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11180477B2 (enExample) |
| EP (1) | EP3411038B1 (enExample) |
| JP (1) | JP6812449B2 (enExample) |
| KR (1) | KR102749892B1 (enExample) |
| CN (1) | CN108495632B (enExample) |
| AR (1) | AR107494A1 (enExample) |
| AU (1) | AU2017214243B2 (enExample) |
| BR (1) | BR112018014712B1 (enExample) |
| CA (1) | CA3011809C (enExample) |
| CO (1) | CO2018007008A2 (enExample) |
| ES (1) | ES2834608T3 (enExample) |
| IL (1) | IL260665B (enExample) |
| MX (1) | MX378363B (enExample) |
| MY (1) | MY185367A (enExample) |
| RU (1) | RU2733376C2 (enExample) |
| TW (1) | TWI745345B (enExample) |
| WO (1) | WO2017134051A1 (enExample) |
| ZA (1) | ZA201805790B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383920B (es) | 2016-05-26 | 2025-03-14 | Recurium Ip Holdings Llc | Compuestos inhibidores de egfr. |
| CN107556293B (zh) * | 2017-09-19 | 2019-12-03 | 福建省微生物研究所 | 一种奥西替尼的合成工艺 |
| WO2021111462A1 (en) * | 2019-12-02 | 2021-06-10 | Natco Pharma Limited | An improved process for the preparation of osimertinib mesylate |
| US11780824B2 (en) * | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
| JP2024530782A (ja) | 2021-09-02 | 2024-08-23 | シントン・ビー．ブイ． | オシメルチニブの製造方法 |
| WO2025124936A1 (en) | 2023-12-15 | 2025-06-19 | Synthon B.V. | A process for making osimertinib |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070401A (en) * | 1972-02-19 | 1978-01-24 | Mitsui Toatsu Chemicals Inc. | Method for the preparation of a halogenated aromatic amine |
| EP4119551A1 (en) * | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| EP3778584A1 (en) * | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| CN104817541B (zh) * | 2015-05-11 | 2017-06-16 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的合成方法 |
-
2017
- 2017-01-26 TW TW106103351A patent/TWI745345B/zh active
- 2017-01-31 ES ES17703696T patent/ES2834608T3/es active Active
- 2017-01-31 CA CA3011809A patent/CA3011809C/en active Active
- 2017-01-31 AU AU2017214243A patent/AU2017214243B2/en active Active
- 2017-01-31 CN CN201780007929.9A patent/CN108495632B/zh active Active
- 2017-01-31 KR KR1020187025038A patent/KR102749892B1/ko active Active
- 2017-01-31 BR BR112018014712-5A patent/BR112018014712B1/pt active IP Right Grant
- 2017-01-31 JP JP2018538156A patent/JP6812449B2/ja active Active
- 2017-01-31 WO PCT/EP2017/052050 patent/WO2017134051A1/en not_active Ceased
- 2017-01-31 MY MYPI2018702645A patent/MY185367A/en unknown
- 2017-01-31 RU RU2018130327A patent/RU2733376C2/ru active
- 2017-01-31 US US16/074,119 patent/US11180477B2/en active Active
- 2017-01-31 EP EP17703696.9A patent/EP3411038B1/en active Active
- 2017-01-31 MX MX2018008966A patent/MX378363B/es unknown
- 2017-01-31 AR ARP170100246A patent/AR107494A1/es active IP Right Grant
-
2018
- 2018-07-04 CO CONC2018/0007008A patent/CO2018007008A2/es unknown
- 2018-07-19 IL IL260665A patent/IL260665B/en unknown
- 2018-08-29 ZA ZA2018/05790A patent/ZA201805790B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6812449B2 (ja) | 2021-01-13 |
| RU2018130327A3 (enExample) | 2020-03-26 |
| MY185367A (en) | 2021-05-11 |
| CA3011809C (en) | 2024-02-27 |
| RU2733376C2 (ru) | 2020-10-01 |
| ZA201805790B (en) | 2024-10-30 |
| AU2017214243B2 (en) | 2019-07-18 |
| AU2017214243A1 (en) | 2018-09-06 |
| CA3011809A1 (en) | 2017-08-10 |
| CN108495632B (zh) | 2021-12-31 |
| EP3411038A1 (en) | 2018-12-12 |
| ES2834608T3 (es) | 2021-06-18 |
| TWI745345B (zh) | 2021-11-11 |
| WO2017134051A1 (en) | 2017-08-10 |
| MX378363B (es) | 2025-03-10 |
| KR102749892B1 (ko) | 2025-01-07 |
| CN108495632A (zh) | 2018-09-04 |
| TW201736364A (zh) | 2017-10-16 |
| EP3411038B1 (en) | 2020-09-09 |
| BR112018014712A2 (pt) | 2018-12-11 |
| US11180477B2 (en) | 2021-11-23 |
| IL260665B (en) | 2021-08-31 |
| JP2019508387A (ja) | 2019-03-28 |
| BR112018014712B1 (pt) | 2023-10-31 |
| KR20180101610A (ko) | 2018-09-12 |
| RU2018130327A (ru) | 2020-03-04 |
| MX2018008966A (es) | 2018-09-03 |
| AR107494A1 (es) | 2018-05-02 |
| US20210122734A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018007008A2 (es) | "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo" | |
| CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
| MX2018014116A (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo. | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
| BR112017006116A2 (pt) | processos de preparação de compostos e compostos | |
| CU24488B1 (es) | Nanopartículas terapéuticas que comprenden un ácido hidrófobo y un agente terapéutico útiles para diferentes tipos de cáncer y proceso de preparación de las mismas | |
| MX375099B (es) | Derivados de aminotiazol útiles como agentes antivíricos. | |
| CO2017010806A2 (es) | Método para manufacturar compuesto novedoso que contiene nitrógeno o sal del mismo e intermediario de manufacturación del compuesto novedoso que contiene nitrógeno o sal del mismo | |
| BR112019001980A2 (pt) | inibidor de ido1 e método de preparação e aplicação do mesmo | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| DOP2017000064A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| BR112018003800A2 (pt) | derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização | |
| MX2025003091A (es) | Metodo para producir derivado de heterociclideno acetamida | |
| MX2017006200A (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
| BR112018070345A2 (pt) | processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas | |
| MX2018007415A (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida. | |
| CO2022008127A2 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina | |
| MX2020012065A (es) | Compuestos de ciclopentano. | |
| MX2020004050A (es) | Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. |